Sergio López
About Sergio López
Sergio López is the Hematology Product Manager at Bristol Myers Squibb in the Greater Madrid Metropolitan Area.
Current Role at Bristol Myers Squibb
Sergio López currently serves as the Hematology Product Manager at Bristol Myers Squibb in the Greater Madrid Metropolitan Area. In this role, which he started in November 2020, he is responsible for the commercial strategy of products such as Reblozyl (luspatercept), Onureg (oral azacitidine), and Opdivo (nivolumab). These products are targeted towards conditions like β-thalassemia, Acute Myeloid Leukemia, and Hodgkin Lymphoma.
Previous Experience at Bristol Myers Squibb
Before his current role, Sergio López worked at Bristol Myers Squibb as a Hematology Marketing Specialist. His tenure in this position lasted from 2019 to 2020 for one year, during which he was based in Madrid, Community of Madrid, Spain.
Work History
Sergio López has accumulated diverse experience in the pharmaceutical industry. Prior to joining Bristol Myers Squibb, he worked at The Janssen Pharmaceutical Companies of Johnson & Johnson in Oncology Marketing for eight months in 2019, and at Publicis Health as a Medical Writer from 2017 to 2018 in Madrid, Community of Madrid, Spain.
Educational Background
Sergio López has an extensive educational background, with a focus on pharmacy and pharmaceutical marketing. He earned a Bachelor of Pharmacy from Universidad Complutense de Madrid over five years, from 2013 to 2018. He also participated in an Erasmus exchange program at the National & Kapodistrian University of Athens from 2016 to 2017. Furthermore, he completed an MBA in Pharmaceutical & Biotechnology Companies from EPHOS, where he specialized in Pharmaceutical Marketing and Management, from 2018 to 2019.
Industry Interests and Skills
Sergio López has a keen interest in digital innovation and market trends, particularly in their applications within the healthcare sector. He is proactive, creative, and determined, always looking to face new challenges. Staying updated on new movements in the pharmaceutical industry is a priority for him, as it allows him to continually improve and adapt.